Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Life Science Stocks Hit New Highs: ABAX, AMRI, QDEL, RGDX 0 comments
    Jul 8, 2013 1:16 PM | about stocks: ABAX, AMRI, QDEL, RGDX

    Life Science Stocks Are Mixed-Biopharma Weak But Diagnostics Strong

    The life science sector traded along with NASDAQ today so as the NAZ sold off (tech stock weakness) biotech followed. The IBB (181.51) off 0.58% could not regain momentum as of mid-day trading after a 3 day rally. Profit taking was evident in some larger cap biopharmaceutical stocks: Alkermes (NASDAQ:ALKS), Alexion (NASDAQ:ALXN), Biogen Idec (NASDAQ:BIIB), Biomarin (NASDAQ:BMRN), and Regeneron (NASDAQ:REGN) but there were many movers in mid caps with more than half of the 50 stocks we track green. High flyers of note among mid-caps are Celldex (CLDX) down 4.4% and Sarepeta (NASDAQ:SRPT) up 4% both on high volume.

    Albany Molecular (NASDAQ:AMRI) hit a 2013 high of $13.69 today. We recommended the stock at $4.68 in Feb 2011.

    A Few Big Winners Today -AACC Coming Up At End of Month-DX Sector Seasonal Strength

    Response Genetics (NASDAQ:RGDX)

    Response Genetics (RGDX) soared on good volume with news that it executed a contract with Blue Cross and Blue Shield of Illlinois so that oncologists and pathologists affiliated with the plan can offer the Company's predictive suite of molecular tests for cancer.The stock is thinly traded but hit a YTD high today up 14%. We added the stock at $1.50 in 2012 and reiterated at $1.10 earlier this year.

    Quidel (NASDAQ:QDEL)

    Quidel (QDEL) briefly hit a new high today at $28.51 on news today that it received FDA clearance for its Sofia Streptococcus A test FIA Test. Revenues are expected to grow to $183M in 2013 with an EPS of $0.37.We added the stock to the Rayno Life Science Portfolio at $14.40 in June 2010.

    Other Rayno Diagnostic in the green today are Abaxis (NASDAQ:ABAX)-2013 high, Alere (NYSE:ALR), Qiagen (NASDAQ:QGEN), Sequenom (NASDAQ:SQNM), Thermo Fisher (NYSE:TMO) and Vermillion (NASDAQ:VRML). Many of the diagnostics and tools stocks should perk up with news prior to and during the AACC Meeting in Houston July 28th.

    Disclosure: I am long ALR, RGDX.

    Stocks: ABAX, AMRI, QDEL, RGDX
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.